• Je něco špatně v tomto záznamu ?

Pulmonary thromboembolism in congenital heart defects with severe pulmonary arterial hypertension

Monika Kaldarárová, Iveta Šimková, Tatiana Valkovičová, Anna Remková, Vladimír Neuschl

. 2013 ; 55 (2) : 209-214. [epub] e170-e175

Jazyk angličtina Země Česko

Perzistentní odkaz   https://www.medvik.cz/link/bmc13021653

Congenital heart defect (CHD) with shunt can lead to severe, even irreversible pulmonary arterial hypertension (PAH); in extreme form to Eisenmenger syndrome (ES). Despite relatively good long-term survival, these patients often suffer from cyanosis and multisystemic dysfunction, where pulmonary artery thrombosis can be a potentially fatal complication. Together with bleeding these are the most frequent causes of non-cardiac death in patients with severe PAH due to CHD.Patients and methodsProspective study of 40 patients with severe PAH due to CHD (28 female/12 male, median age 41.5 years) was performed, with the aim to analyze the presence of pulmonary artery thrombosis and correlating anatomical and laboratory risk factors.ResultsPrevious thrombosis and/or thromboembolic event was found in 7 patients (17.5%). Significant differences in cyanotic vs non-cyanotic patients were in red blood count parameters: median hemoglobin level 195 vs 141 (p<0.0001), median erythrocytes count 6.62 vs 4.88×1012/l (p<0.0001), median hematocrit 0.58 vs 0.44 (p<0.0001). Laboratory findings causing increased risk for thrombosis were increased thrombocytes aggregation in 15 patients (37.5%), hypercoagulation in 5 patients (12.5%) and endothelial dysfunction in 8 patients (20%). Anatomical risk factor—severe pulmonary artery dilatation (>40 mm in female and >45 mm in male) was found in 19 patients (51.4%).ConclusionsPatients with severe PAH due to CHD represent a high-risk group for pulmonary artery thrombosis with morphological and flow pathology combined with secondary erythrocytosis and coagulation abnormalities. A relatively high incidence of platelet hyperaggregability shown in our study would propose that aspirin therapy might be considered in some highly selected patients with severe PAH due to CHD. Further studies though are needed to support this data.

000      
00000naa a2200000 a 4500
001      
bmc13021653
003      
CZ-PrNML
005      
20130809142537.0
007      
ta
008      
130611s2013 xr da f 000 0eng||
009      
AR
024    7_
$2 doi $a 10.1016/j.crvasa.2013.03.006
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a eng $b slo
044    __
$a xr
100    1_
$a Kaldarárová, Monika. $7 xx0320891 $u Národný ústav srdcových a cievnych chorôb, a. s. – Detské kardiocentrum, Bratislava, Slovenská republika
245    10
$a Pulmonary thromboembolism in congenital heart defects with severe pulmonary arterial hypertension / $c Monika Kaldarárová, Iveta Šimková, Tatiana Valkovičová, Anna Remková, Vladimír Neuschl
520    9_
$a Congenital heart defect (CHD) with shunt can lead to severe, even irreversible pulmonary arterial hypertension (PAH); in extreme form to Eisenmenger syndrome (ES). Despite relatively good long-term survival, these patients often suffer from cyanosis and multisystemic dysfunction, where pulmonary artery thrombosis can be a potentially fatal complication. Together with bleeding these are the most frequent causes of non-cardiac death in patients with severe PAH due to CHD.Patients and methodsProspective study of 40 patients with severe PAH due to CHD (28 female/12 male, median age 41.5 years) was performed, with the aim to analyze the presence of pulmonary artery thrombosis and correlating anatomical and laboratory risk factors.ResultsPrevious thrombosis and/or thromboembolic event was found in 7 patients (17.5%). Significant differences in cyanotic vs non-cyanotic patients were in red blood count parameters: median hemoglobin level 195 vs 141 (p<0.0001), median erythrocytes count 6.62 vs 4.88×1012/l (p<0.0001), median hematocrit 0.58 vs 0.44 (p<0.0001). Laboratory findings causing increased risk for thrombosis were increased thrombocytes aggregation in 15 patients (37.5%), hypercoagulation in 5 patients (12.5%) and endothelial dysfunction in 8 patients (20%). Anatomical risk factor—severe pulmonary artery dilatation (>40 mm in female and >45 mm in male) was found in 19 patients (51.4%).ConclusionsPatients with severe PAH due to CHD represent a high-risk group for pulmonary artery thrombosis with morphological and flow pathology combined with secondary erythrocytosis and coagulation abnormalities. A relatively high incidence of platelet hyperaggregability shown in our study would propose that aspirin therapy might be considered in some highly selected patients with severe PAH due to CHD. Further studies though are needed to support this data.
650    _2
$a prospektivní studie $7 D011446
650    12
$a vrozené srdeční vady $x etiologie $x farmakoterapie $x patologie $7 D006330
650    12
$a plicní hypertenze $x patofyziologie $x patologie $7 D006976
650    _2
$a arteria pulmonalis $x patologie $7 D011651
650    _2
$a dilatace patologická $7 D004108
650    _2
$a cyanóza $7 D003490
650    _2
$a Eisenmengerův syndrom $x farmakoterapie $x patofyziologie $x patologie $7 D004541
650    12
$a plicní embolie $x etiologie $x farmakoterapie $x patologie $x prevence a kontrola $7 D011655
650    _2
$a krvácení $x prevence a kontrola $7 D006470
650    _2
$a rizikové faktory $7 D012307
650    _2
$a antikoagulancia $x terapeutické užití $7 D000925
650    _2
$a Aspirin $x terapeutické užití $7 D001241
650    _2
$a koagulopatie $x diagnóza $x etiologie $x farmakoterapie $x patologie $7 D001778
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a senioři $7 D000368
650    _2
$a ženské pohlaví $7 D005260
700    1_
$a Šimková, Iveta. $7 jx20120222045 $u Kardiologická klinika Slovenskej zdravotníckej univerzity a Národného ústavu srdcových a cievnych chorôb, a. s., Bratislava, Slovenská republika
700    1_
$a Valkovičová, Tatiana. $7 _AN073351 $u Kardiologická klinika Slovenskej zdravotníckej univerzity a Národného ústavu srdcových a cievnych chorôb, a. s., Bratislava, Slovenská republika
700    1_
$a Remková, Anna, $d 1954- $7 nlk20050173079 $u Centrum hemostázy a trombózy HemoMedika, Bratislava, Slovenská republika
700    1_
$a Neuschl, Vladimír. $7 _AN073352 $u Inštitút zobrazovacej diagnostiky, Trnava, Slovenská republika
773    0_
$t Cor et vasa $x 0010-8650 $g Roč. 55, č. 2 (2013), s. 209-214 (e e170-e175) $w MED00010972
910    __
$a ABA008 $b A 2980 $c 438 $y 3 $z 0
990    __
$a 20130424185703 $b ABA008
991    __
$a 20130809143039 $b ABA008
999    __
$a ok $b bmc $g 985244 $s 820008
BAS    __
$a 3
BMC    __
$a 2013 $b 55 $c 2 $d 209-214 $f e170-e175 $i 0010-8650 $m Cor et Vasa (Brno) $n Cor Vasa (Brno Print) $x MED00010972
LZP    __
$c NLK121 $d 20130809 $a NLK 2013-31/vt

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...